poudre pour solution injectable ou pour perfusion

DRUG7 trials

Sponsors

Centre Hospitalier Sud Francilien, Assistance Publique Hopitaux De Paris, Cabaletta Bio Inc., Centre Hospitalier Universitaire De Lille, Hopital Fondation Adolphe De Rothschild

Conditions

55-65 years old patients with ASA > 3 or patients over 65 years old with any ASAActive Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common severe manifestation of SLECardiogenic ShockIntubationPatient with severe eye chemical burnsPatients (male or female) ≥18 years old with R/R AML that expresses CD19 by Flow-cytometryparaneoplastic sensory neuropathy with anti-Hu antibodiesrequiring rapid sequence induction considered to have a full stomach during the anesthesia consultation (scheduled or urgent).

Phase 1

A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Systemic Lupus Erythematosus

RecruitingCTIS2023-507613-10-01

Cabaletta Bio Inc.Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by autoantibody production and abnormal B cell function. SLE presents with fluctuating severity and may cause tissue damage in a variety of organs over time. Lupus nephritis (LN) is a common severe manifestation of SLE, which can lead to significant morbidity and mortality.

Start: 2025-03-31Target: 6Updated: 2026-01-26

CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML expressing CD19.”

RecruitingCTIS2023-509212-29-01

Centre Hospitalier Universitaire De LillePatients (male or female) ≥18 years old with R/R AML that expresses CD19 by Flow-cytometry

Start: 2025-07-10Target: 5Updated: 2025-10-20

Phase 2

Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplastic sensory neuropathy (NESPA).

RecruitingCTIS2023-506942-22-01

Assistance Publique Hopitaux De Parisparaneoplastic sensory neuropathy with anti-Hu antibodies

Start: 2025-01-10Target: 21Updated: 2025-04-23

SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre, single-arm, open-label phase II trial

Not yet recruitingCTIS2023-509713-37-00

Hopital Fondation Adolphe De RothschildPatient with severe eye chemical burns

Target: 21Updated: 2025-12-09

Phase 3

Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock

RecruitingCTIS2024-513811-29-00

CHRU De NancyCardiogenic Shock

Start: 2023-07-03Target: 610Updated: 2025-07-30

Phase 4

Impact of opioids on heart rate during rapid sequence intubation : Double-blind randomized controlled study (CANDY-CRASH).

Active, not recruitingCTIS2022-501500-10-00

Centre Hospitalier Sud Francilien55-65 years old patients with ASA > 3 or patients over 65 years old with any ASA, requiring rapid sequence induction considered to have a full stomach during the anesthesia consultation (scheduled or urgent).

Start: 2023-05-16Target: 150Updated: 2022-11-21

Opioid-Free Analgesia In Intensive Care Unit : A Prospective, Monocentric, Randomized, Double-Blind, Feasibility Clinical Trial

Active, not recruitingCTIS2024-517770-14-00

Centre Hospitalier Universitaire De NimesIntubation

Start: 2025-11-24Target: 50Updated: 2025-11-19